These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31330122)

  • 21. Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects.
    Borgs L; Peyre E; Alix P; Hanon K; Grobarczyk B; Godin JD; Purnelle A; Krusy N; Maquet P; Lefebvre P; Seutin V; Malgrange B; Nguyen L
    Sci Rep; 2016 Sep; 6():33377. PubMed ID: 27640816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function.
    Ohtonen S; Giudice L; Jäntti H; Fazaludeen MF; Shakirzyanova A; Gómez-Budia M; Välimäki NN; Niskanen J; Korvenlaita N; Fagerlund I; Koistinaho J; Amiry-Moghaddam M; Savchenko E; Roybon L; Lehtonen Š; Korhonen P; Malm T
    Sci Rep; 2023 Dec; 13(1):22118. PubMed ID: 38092815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
    Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
    Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exhaustion of mitochondrial and autophagic reserve may contribute to the development of LRRK2
    Juárez-Flores DL; González-Casacuberta I; Ezquerra M; Bañó M; Carmona-Pontaque F; Catalán-García M; Guitart-Mampel M; Rivero JJ; Tobias E; Milisenda JC; Tolosa E; Marti MJ; Fernández-Santiago R; Cardellach F; Morén C; Garrabou G
    J Transl Med; 2018 Jun; 16(1):160. PubMed ID: 29884186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.
    Hassin-Baer S; Laitman Y; Azizi E; Molchadski I; Galore-Haskel G; Barak F; Cohen OS; Friedman E
    J Neurol; 2009 Mar; 256(3):483-7. PubMed ID: 19412725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired serine metabolism complements LRRK2-G2019S pathogenicity in PD patients.
    Nickels SL; Walter J; Bolognin S; Gérard D; Jaeger C; Qing X; Tisserand J; Jarazo J; Hemmer K; Harms A; Halder R; Lucarelli P; Berger E; Antony PMA; Glaab E; Hankemeier T; Klein C; Sauter T; Sinkkonen L; Schwamborn JC
    Parkinsonism Relat Disord; 2019 Oct; 67():48-55. PubMed ID: 31621607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The LRRK2 G2019S mutation alters astrocyte-to-neuron communication via extracellular vesicles and induces neuron atrophy in a human iPSC-derived model of Parkinson's disease.
    de Rus Jacquet A; Tancredi JL; Lemire AL; DeSantis MC; Li WP; O'Shea EK
    Elife; 2021 Sep; 10():. PubMed ID: 34590578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson's disease.
    du Toit N; van Coller R; Anderson DG; Carr J; Bardien S
    Neurogenetics; 2019 Oct; 20(4):215-218. PubMed ID: 31493133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modeling Parkinson's disease using induced pluripotent stem cells.
    Byers B; Lee HL; Reijo Pera R
    Curr Neurol Neurosci Rep; 2012 Jun; 12(3):237-42. PubMed ID: 22538490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality.
    Walter J; Bolognin S; Antony PMA; Nickels SL; Poovathingal SK; Salamanca L; Magni S; Perfeito R; Hoel F; Qing X; Jarazo J; Arias-Fuenzalida J; Ignac T; Monzel AS; Gonzalez-Cano L; Pereira de Almeida L; Skupin A; Tronstad KJ; Schwamborn JC
    Stem Cell Reports; 2019 May; 12(5):878-889. PubMed ID: 30982740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons.
    López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R
    J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurite Collapse and Altered ER Ca
    Korecka JA; Talbot S; Osborn TM; de Leeuw SM; Levy SA; Ferrari EJ; Moskites A; Atkinson E; Jodelka FM; Hinrich AJ; Hastings ML; Woolf CJ; Hallett PJ; Isacson O
    Stem Cell Reports; 2019 Jan; 12(1):29-41. PubMed ID: 30595548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.
    Sanders LH; Laganière J; Cooper O; Mak SK; Vu BJ; Huang YA; Paschon DE; Vangipuram M; Sundararajan R; Urnov FD; Langston JW; Gregory PD; Zhang HS; Greenamyre JT; Isacson O; Schüle B
    Neurobiol Dis; 2014 Feb; 62():381-6. PubMed ID: 24148854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leucine rich repeat kinase 2 (LRRK2) GLY2019SER mutation is absent in a second cohort of Nigerian Africans with Parkinson disease.
    Okubadejo NU; Rizig M; Ojo OO; Jonvik H; Oshinaike O; Brown E; Houlden H
    PLoS One; 2018; 13(12):e0207984. PubMed ID: 30507963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.